Clinical Trials Logo

Clinical Trial Summary

The study is designed to demonstrate the therapeutic non-inferiority of the recombinant humanized monoclonal VEGF antibody bevacizumab administered by intravitreal injection in the treatment of AMD in comparison to the related fragment ranibizumab.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00559715
Study type Interventional
Source Klinikum Bremen-Mitte, gGmbH
Contact Bernd Muehlbauer, Professor MD
Phone +49 (0) 421 497 5352
Email b.muehlbauer@pharmakologie-bremen.de
Status Recruiting
Phase Phase 3
Start date August 2008
Completion date August 2010